首页 › 基金 › ArchPoint Investors › CLYM
ArchPoint Investors 对 CLYM 的持仓历史
CLIMB BIO INC · 医疗保健
ArchPoint Investors 在 Q3 2026 的 13F 申报中披露持有 CLYM(CLIMB BIO INC)132,900 股,市值约 US$1.5M,约占其申报组合的 0.32%,在其申报持仓中市值排名第 49 位。 ArchPoint Investors 最近 4 个申报季度中有 4 个季度披露了 CLYM 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
ArchPoint Investors 对 CLYM 的持仓演变
ArchPoint Investors 于 Q4 2025 首次披露 CLYM 持仓:121,400 股(约 US$486K)。 该持仓在 Q2 2026 达到峰值 128,900 股,市值约 US$1.7M。 在 4 次申报中,ArchPoint Investors 2 次增持、0 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 132,900 股、市值约 US$1.5M,环比增持 4,000 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 121.40K | $485.60K | 新进 |
| Q1 2026 | 121.40K | $831.59K | 持有 |
| Q2 2026 | 128.90K | $1.68M | 增持 |
| Q3 2026 | 132.90K | $1.52M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CLYM 与 13F 数据
CLYM(CLIMB BIO INC)属于医疗保健行业。我们追踪的基金中还有 73 只申报持有 CLYM,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$147.4M), BRAIDWELL LP (US$36.5M), Cormorant Asset Management, LP (US$27.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CLYM 的基金
- RA CAPITAL MANAGEMENT, L.P. 11.30M 股 · $147.36M · Q2 2026
- BRAIDWELL LP 2.80M 股 · $36.48M · Q2 2026
- Cormorant Asset Management, LP 2.11M 股 · $27.46M · Q2 2026
- Redmile Group, LLC 1.23M 股 · $15.99M · Q2 2026
- GREAT POINT PARTNERS LLC 1.00M 股 · $13.04M · Q2 2026
- Affinity Asset Advisors, LLC 972.00K 股 · $12.67M · Q2 2026
- ADAR1 Capital Management, LLC 822.65K 股 · $10.73M · Q2 2026
- STEMPOINT CAPITAL LP 742.75K 股 · $9.69M · Q2 2026
- Parkman Healthcare Partners LLC 563.48K 股 · $7.35M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 521.08K 股 · $6.79M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 483.75K 股 · $6.31M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 360.65K 股 · $4.14M · Q3 2026
更多关于 ArchPoint Investors
常见问题
How long has ArchPoint Investors held CLYM?
ArchPoint Investors has disclosed CLYM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is ArchPoint Investors's current position in CLYM?
As of Q3 2026, ArchPoint Investors holds 132.90K shares of CLYM (CLIMB BIO INC), valued at $1.52M, representing 0.32% of its reported portfolio and ranking #49.
Has ArchPoint Investors been buying or selling CLYM?
In the latest 13F filing (Q3 2026), ArchPoint Investors increased its position in CLYM. The position peaked in Q2 2026 at 128.90K shares.
Which other funds hold CLYM?
Other major institutional holders of CLYM include RA CAPITAL MANAGEMENT, L.P., BRAIDWELL LP, Cormorant Asset Management, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.